Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 63739-178

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 63739-178). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mckesson Corporation Dba Sky Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1 (Carton1)

Each tablet of the medication contains 391.5 mg of clopidogrel in bisulfate USP. The dosage and storage information can be seen in the package insert. The unit-dose package is not child-resistant. This medication is for institutional use only. The NDC number is 63739-178-30. For further information about the medication, please visit the website mentioned. The rest of the text is not readable.*

FDA Label Image

Figure1 (Figure1)

This appears to be a table or graph displaying the effects of different proton pump inhibitors (PPIs) on the active metabolite AUC (area under the curve) when co-administered. The PPIs listed are Dexlansoprazole (60 mg), Lansoprazole (30 mg), Pantoprazole (80 mg), and Omeprazole (80 mg). The symbols "T T T T" might indicate statistical significance or dosage timing, but without additional context, it is not possible to determine their meaning.*

FDA Label Image

Figure2 (Figure2)

This is a chart comparing the efficacy of two drugs, Placebo (+ aspirin) and Clopidogrel (+ aspirin), over the course of several months. The chart displays the cumulative event rate (%) and the months of follow-up. Other standard therapies were used alongside the drugs as needed.*

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

This appears to be a comparison of two treatments, "Placebo" and "Clopidogrel," in terms of their impact on mortality rates. The data shows that there were 1845 deaths (8.1%) in the placebo group and 1726 deaths (7.5%) in the clopidogrel group. Additionally, the latter had a 7% proportional risk reduction (p=0.03). The time period of the study ranged from 0 to 28 days after randomization.*

FDA Label Image

Figure5 (Figure5)

This text reports the results of a study evaluating the effectiveness of Clopidogrel in reducing the risk of death, reinfarction, or stroke before the first discharge after an event. The study was conducted with 2310 participants receiving a placebo, of which 10.1% experienced an adverse event, and 2121 participants receiving Clopidogrel, of which 92% experienced a similar event. The text reports a proportional risk reduction of 9% for the group receiving Clopidogrel, and the statistical significance of this outcome (p=0.002). The data is presented over the time since the participants were randomized, up to 28 days.*

FDA Label Image

Figure6 (Figure6)

FDA Label Image

Figure7 (Figure7)

The text is discussing Clopidogrel and its effectiveness in preventing fatal and non-fatal vascular events.*

FDA Label Image

Figure8 (Figure8)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.